Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Harlan Robins sold 492,400 shares of Adaptive Biotechnologies stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the transaction, the insider directly owned 812,058 shares in the company, valued at $17,775,949.62. This represents a 37.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adaptive Biotechnologies Price Performance
Shares of NASDAQ ADPT opened at $22.52 on Wednesday. The firm has a fifty day moving average price of $18.88 and a 200-day moving average price of $16.51. The stock has a market cap of $3.60 billion, a PE ratio of -68.24 and a beta of 2.07. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $23.15.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same period last year, the firm earned ($0.20) EPS. The company's revenue was up 35.1% on a year-over-year basis. On average, research analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.
Analysts Set New Price Targets
Several brokerages have recently commented on ADPT. BTIG Research restated a "buy" rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th. Guggenheim increased their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Monday, June 29th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. JPMorgan Chase & Co. decreased their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 6th. Finally, Morgan Stanley boosted their price target on Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an "equal weight" rating in a report on Thursday, July 9th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $20.83.
Check Out Our Latest Stock Report on Adaptive Biotechnologies
Institutional Trading of Adaptive Biotechnologies
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. lifted its stake in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company's stock worth $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company's stock valued at $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth about $65,942,000. Geode Capital Management LLC increased its holdings in shares of Adaptive Biotechnologies by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company's stock worth $57,041,000 after purchasing an additional 110,825 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Adaptive Biotechnologies by 3.3% in the fourth quarter. State Street Corp now owns 3,181,644 shares of the company's stock worth $51,670,000 after purchasing an additional 102,362 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
